Metastatic Solid Tumor Clinical Trials in Scottsdale, Arizona

4 studies are recruiting for metastatic solid tumor in Scottsdale, Arizona right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of KK2269 in Adult Participants With Solid Tumors

    This is a first-in-human study of KK2269. Part 1 and Part 2 will be conducted as a multicenter, open-label, non-randomized, dose-escalation study. Participants with advanced or metastatic solid tumors for which no standard therapy is available will be enrolled in Part 1. In Part 1, the primary obje…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Mayo Clinic Arizona, Scottsdale, Arizona
    Locations
    32 in total
    Run by
    Kyowa Kirin Co., Ltd.

    See if you can join NCT06266299 on ClinicalTrials.gov

  2. First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

    A multicenter, single-arm, first-in-human study to investigate the safety, pharmacokinetics, and preliminary antitumor activity of PLX-61639 in participants with locally advanced or metastatic, relapsed/refractory, SMARCA4-deficient solid tumors who are intolerant of or have failed available, appro…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Research Site, Scottsdale, Arizona
    Locations
    10 in total
    Run by
    Plexium, Inc.

    See if you can join NCT07284186 on ClinicalTrials.gov

  3. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

    Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    HonorHealth Research Institute, Scottsdale, Arizona
    Locations
    21 in total
    Run by
    Clasp Therapeutics, Inc.

    See if you can join NCT06778863 on ClinicalTrials.gov

  4. A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd) over a range of advanced and/or metastatic solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Mayo Clinic in Arizona, Scottsdale, Arizona
    Locations
    11 in total
    Run by
    GI Innovation, Inc.

    See if you can join NCT05824975 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.